艾司西酞普兰单用与合用氨磺必利治疗重性抑郁症的疗效和安全性  

A control study between escitalopram monotherapy and combination therapy with amisulpride in the treatment of major depression

作　　者：叶萌[1] 周新芳[1] 徐晓津[1] 房茂胜[1] 

机构地区：[1]湖北省武汉市精神卫生中心,430022

出　　处：《精神医学杂志》2013年第4期290-291,共2页Journal of Psychiatry

摘　　要：目的探讨氨磺必利合用艾司西酞普兰治疗重性抑郁症的有效性和安全性。方法 80例重性抑郁症患者随机分为艾司西酞普兰组(对照组)和艾司西酞普兰合用氨磺必利组(研究组)各40例,疗程8周。于治疗前和治疗后第1、2、4、8周末采用汉密尔顿抑郁量表(HAMD)评定疗效,采用不良事件和实验室检查评价安全性。结果两组治疗后第8周末缓解率分别为57.9%和64.9%,差异无统计学意义(χ2=0.384,P>0.05)。两组HAMD评分治疗后均较治疗前显著降低,差异有统计学意义(P<0.05)。研究组在治疗后第1、2周末HAMD评分显著低于对照组,差异有统计学意义(t=2.91,2.72;P<0.05)。两组不良反应均轻微,差异无统计学意义(P>0.05)。结论艾司西酞普兰合用氨磺必利治疗重性抑郁症起效更快。Objective To compare the efficacy ano smety or esc^talopram IllOllOtltt：ta[Jy atJu F with amisulpride in treatment of major depressiom. Methods 80 patients with major depression were randomly divided into study group （40 cases） treated with escitalopram combined with amisulpride and control group （40 cases） treated with escitalopram monotherapy for 8 weeks. All patients were assessed with Hamilton Depression Rating Scale （HAMD） at baseline and at the 1st, 2nd, 4th, 8th weekend of the treatment to evaluate the efficacy. The safety were evaluated by using self-reported adverse events and laboratory examination. Results At the end of the 8 - week treatment, there was no significant difference in remission rate between study group and control group （64.9% vs. 57.9% ; X2 =0. 384, P 〉 0.05）. Socres of HAMD in both groups decreased significantly compared with the baseline （ P 〈 0.05 ）. Scores of HAMD in study group were significantly lower than those in control group at the end of the 1 st, 2nd week of the treatment （ t = 2.91,2.72 respectively, P 〈0.05）. Side effects were mild in both groups and there was no significant difference in the frequency of side effects between the two groups （ P 〉 0.05 ）. Conclusion Escitalopram combined with amisulpride takes effect faster than escitalopram monotherapy in the treatment of major depression.

关 键 词：艾司西酞普兰 氨磺必利 重性抑郁症 

分 类 号：R749.4[医药卫生—神经病学与精神病学]